Open Access<p>Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best–Worst Scaling</p>
Author(s) -
Martine C. Maculaitis,
Xianchen Liu,
Oliver Will,
Madelyn S. Hanson,
Lynn McRoy,
Alexandra Berk,
Melissa Crastnopol
Publication year - 2020
Publication title -
patient preference and adherence
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.885
H-Index - 48
ISSN - 1177-889X
DOI - 10.2147/ppa.s254934
Subject(s) - medicine , neutropenia , dosing , febrile neutropenia , adverse effect , regimen , diarrhea , oncology , toxicity
To understand and compare preferences for dosing- and toxicity-related attributes associated with selective cyclin-dependent 4/6 kinase inhibitors regimens among US oncologists and patients.